284 related articles for article (PubMed ID: 27191498)
1. Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells.
Höhn A; Krüger K; Skowron MA; Bormann S; Schumacher L; Schulz WA; Hoffmann MJ; Niegisch G; Fritz G
Oncotarget; 2016 Jul; 7(27):41320-41335. PubMed ID: 27191498
[TBL] [Abstract][Full Text] [Related]
2. Transcribed ultraconserved region Uc.63+ promotes resistance to cisplatin through regulation of androgen receptor signaling in bladder cancer.
Sekino Y; Sakamoto N; Ishikawa A; Honma R; Shigematsu Y; Hayashi T; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
Oncol Rep; 2019 May; 41(5):3111-3118. PubMed ID: 30864720
[TBL] [Abstract][Full Text] [Related]
3. Targeting urothelial carcinoma cells by combining cisplatin with a specific inhibitor of the autophagy-inducing class III PtdIns3K complex.
Schlütermann D; Skowron MA; Berleth N; Böhler P; Deitersen J; Stuhldreier F; Wallot-Hieke N; Wu W; Peter C; Hoffmann MJ; Niegisch G; Stork B
Urol Oncol; 2018 Apr; 36(4):160.e1-160.e13. PubMed ID: 29276062
[TBL] [Abstract][Full Text] [Related]
4. Lovastatin prevents cisplatin-induced activation of pro-apoptotic DNA damage response (DDR) of renal tubular epithelial cells.
Krüger K; Ziegler V; Hartmann C; Henninger C; Thomale J; Schupp N; Fritz G
Toxicol Appl Pharmacol; 2016 Feb; 292():103-14. PubMed ID: 26739623
[TBL] [Abstract][Full Text] [Related]
5. Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines.
Skowron MA; Melnikova M; van Roermund JGH; Romano A; Albers P; Thomale J; Schulz WA; Niegisch G; Hoffmann MJ
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29462944
[TBL] [Abstract][Full Text] [Related]
6. MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial Carcinoma.
Ho IL; Kuo KL; Liu SH; Chang HC; Hsieh JT; Wu JT; Chiang CK; Lin WC; Tsai YC; Chou CT; Hsu CH; Pu YS; Shi CS; Huang KH
Sci Rep; 2015 Nov; 5():16948. PubMed ID: 26592553
[TBL] [Abstract][Full Text] [Related]
7. Combination of androgen receptor inhibitor and cisplatin, an effective treatment strategy for urothelial carcinoma of the bladder.
Tyagi A; Chandrasekaran B; Kolluru V; Rai S; Jordan AC; Houda A; Messer J; Ankem M; Damodaran C; Haddad A
Urol Oncol; 2019 Jul; 37(7):492-502. PubMed ID: 31006613
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of grade dependent autophagy in urothelial carcinoma increases cell death under nutritional limiting condition and potentiates the cytotoxicity of chemotherapeutic agent.
Ojha R; Singh SK; Bhattacharyya S; Dhanda RS; Rakha A; Mandal AK; Jha V
J Urol; 2014 Jun; 191(6):1889-98. PubMed ID: 24440234
[TBL] [Abstract][Full Text] [Related]
9. Targeting HNRNPU to overcome cisplatin resistance in bladder cancer.
Shi ZD; Hao L; Han XX; Wu ZX; Pang K; Dong Y; Qin JX; Wang GY; Zhang XM; Xia T; Liang Q; Zhao Y; Li R; Zhang SQ; Zhang JH; Chen JG; Wang GC; Chen ZS; Han CH
Mol Cancer; 2022 Feb; 21(1):37. PubMed ID: 35130920
[TBL] [Abstract][Full Text] [Related]
10. Trifluoperazine, an Antipsychotic Drug, Effectively Reduces Drug Resistance in Cisplatin-Resistant Urothelial Carcinoma Cells via Suppressing Bcl-xL: An In Vitro and In Vivo Study.
Kuo KL; Liu SH; Lin WC; Hsu FS; Chow PM; Chang YW; Yang SP; Shi CS; Hsu CH; Liao SM; Chang HC; Huang KH
Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31262032
[TBL] [Abstract][Full Text] [Related]
11. Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.
Isono M; Hoffmann MJ; Pinkerneil M; Sato A; Michaelis M; Cinatl J; Niegisch G; Schulz WA
J Exp Clin Cancer Res; 2017 Jan; 36(1):1. PubMed ID: 28049532
[TBL] [Abstract][Full Text] [Related]
12. Bacillus Calmette-Guerin inhibits apoptosis in human urothelial carcinoma cell lines in response to cytotoxic injury.
Chen F; Zhang G; Cao Y; Payne R; See WA
J Urol; 2007 Nov; 178(5):2166-70. PubMed ID: 17870116
[TBL] [Abstract][Full Text] [Related]
13. P-glycoprotein depresses cisplatin sensitivity in L1210 cells by inhibiting cisplatin-induced caspase-3 activation.
Gibalová L; Sereš M; Rusnák A; Ditte P; Labudová M; Uhrík B; Pastorek J; Sedlák J; Breier A; Sulová Z
Toxicol In Vitro; 2012 Apr; 26(3):435-44. PubMed ID: 22269388
[TBL] [Abstract][Full Text] [Related]
14. Compensatory combination of romidepsin with gemcitabine and cisplatin to effectively and safely control urothelial carcinoma.
Pattarawat P; Hong T; Wallace S; Hu Y; Donnell R; Wang TH; Tsai CL; Wang J; Wang HR
Br J Cancer; 2020 Jul; 123(2):226-239. PubMed ID: 32390005
[TBL] [Abstract][Full Text] [Related]
15. Platinum-induced kidney damage: Unraveling the DNA damage response (DDR) of renal tubular epithelial and glomerular endothelial cells following platinum injury.
Krüger K; Thomale J; Stojanović N; Osmak M; Henninger C; Bormann S; Fritz G
Biochim Biophys Acta; 2015 Mar; 1853(3):685-98. PubMed ID: 25565603
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting WEE1 Augments the Antitumor Efficacy of Cisplatin in Urothelial Carcinoma by Enhancing the DNA Damage Process.
Su YL; Xiao LY; Huang SY; Wu CC; Chang LC; Chen YH; Luo HL; Huang CC; Liu TT; Peng JM
Cells; 2023 May; 12(11):. PubMed ID: 37296592
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder.
Wang WJ; Li CF; Chu YY; Wang YH; Hour TC; Yen CJ; Chang WC; Wang JM
Clin Cancer Res; 2017 Jan; 23(2):503-513. PubMed ID: 27435393
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor‑related apoptosis‑inducing ligand as a therapeutic option in urothelial cancer cells with acquired resistance against first‑line chemotherapy.
Vallo S; Stege H; Berg M; Michaelis M; Winkelmann R; Rothweiler F; Cinatl J
Oncol Rep; 2020 Apr; 43(4):1331-1337. PubMed ID: 32020226
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy for advanced transitional cell carcinoma of the urothelium: cisplatin or carboplatin?
Culine S
Eur Urol; 2007 Jul; 52(1):9-10. PubMed ID: 17239527
[No Abstract] [Full Text] [Related]
[Next] [New Search]
